Skip to main content
. 2022 Mar 14;23:212. doi: 10.1186/s13063-022-06028-y
Outcome Measurement tool Measurement occasions
Primary outcome
 Pain severity Pain Severity Score of the Brief Pain Inventory Baseline, weeks 2, 4, 6 and 12
Secondary outcomes
 Physical functioning (generic) Pain Interference Score of the Brief Pain Inventory. Baseline, weeks 2, 4, 6 and 12
 Physical functioning (condition-specific) Roland-Morris Disability Questionnaire (24 items, for participants reporting low back pain only) and Neck Disability Questionnaire (for participants reporting neck pain only) Baseline and 6 weeks
 Time to recovery (average daily pain of 0 or 1 of 10 for the past seven consecutive days) Pain diary Daily until recovery or up to 12 weeks
 Quality of life (physical) SF-12 Baseline, weeks 2, 4, 6 and 12
 Quality of life (mental) SF-12 Baseline, weeks 2, 4, 6 and 12
 Participants’ rating of global improvement Global Perceived Effect scale Baseline, weeks 2, 4, 6 and 12
Other outcomes
 Adverse events Self-report and doctor report

Self-report at weeks 2, 4, 6 and 12

Doctor report after each follow-up visit

 Work absenteeism Self-report Baseline, weeks 2, 4, 6 and 12
 Use of treatment or health care services Self-report Baseline, weeks 2, 4, 6 and 12
 Compliance to study medication Self-reported adherence recorded in a medication diary compared against doctor prescription data, supported by returned medicine count

Medicine diary is recorded daily over 6 weeks

Doctor prescription data at each visit

Returned medicine count at end of treatment period (≤6 weeks)

 Success of blinding Participants are asked to estimate their allocation group as active opioid, inactive placebo or do not know Week 6
Long-term outcomes
 Pain severity Pain Severity Score of the Brief Pain Inventory Weeks 26 and 52
 Use of treatment or health care services Self-report Weeks 26 and 52 if still experiencing low back pain and/or neck pain (> 1/10)
 Risk of misuse Current Opioid Misuse Measure Weeks 12, 26 and 52